NovartisNovartis posted strong results for its wet age-related macular degeneration (AMD) drug, by showing superiority against Eylea in Phase 3 trials. The data sets Novartis up to take a chunk of the nearly $5 billion that Eylea and Lucentis, the leading products in the market, reap annually.

 

Bron: Pharmafile | lees verder..